<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00929877</url>
  </required_header>
  <id_info>
    <org_study_id>KETOP_C_03968</org_study_id>
    <secondary_id>2008-008265-36(EudraCT)</secondary_id>
    <nct_id>NCT00929877</nct_id>
  </id_info>
  <brief_title>KRYSTAL- KetopRofen lYsinate Sore ThroAt Lozenges</brief_title>
  <official_title>A Randomised Double Blind, Placebo-controlled, Parallel-group Study of the Efficacy and Safety of 2 Doses of Ketoprofen Lysinate Lozenges (6.25 mg &amp; 12.5 mg) in Patients With Sore Throat</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      Primary Objective:&#xD;
&#xD;
      To compare the single-dose efficacy of ketoprofen lysinate lozenges (6.25 mg and 12.5 mg&#xD;
      ketoprofen base) with placebo, on total pain relief summed over 15 to 120 min (TOTPAR15-120)&#xD;
      after the first intake of study drug.&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
      To compare the single-dose efficacy of ketoprofen lysinate lozenges (6.25mg and 12.5mg ) with&#xD;
      placebo after the first intake on:&#xD;
&#xD;
        -  the total pain relief summed over 15 to 360min (TOTPAR15-360)&#xD;
&#xD;
        -  the changes from baseline of global throat pain intensity assessed over 15 to 120min and&#xD;
           over 15 to 360min.&#xD;
&#xD;
        -  the changes from baseline of throat soreness over 15 to 120min and over 15 to 360min&#xD;
&#xD;
        -  the changes from baseline of swollen throat over 15 to 120min and over 15 to 360min To&#xD;
           compare pain relief, global throat pain intensity, throat soreness and swollen throat in&#xD;
           the evening of days 1, 2 and 3&#xD;
&#xD;
      To evaluate the safety of ketoprofen lysinate lozenges (6.25mg and 12.5mg ) and placebo at&#xD;
      follow-up visit on:&#xD;
&#xD;
      Day 4: - adverse events and clinical examination Day 7: - adverse events reporting (followed&#xD;
      by a clinical examination if needed)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The TOTPAR15-120 which is the sum of each pain relief scale score</measure>
    <time_frame>measured every 15 minutes during the 2 hours following the first study drug intake</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The TOTPAR15-360 which is the sum of each pain relief scale score</measure>
    <time_frame>Measured every 15 minutes during the 2 hours following the first study drug intake at study site then every hour up to 6 hours as outpatient.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The global throat pain intensity</measure>
    <time_frame>assessed every 15 min during 2 hours after the first study drug intake</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The morning pain relief scale score</measure>
    <time_frame>measured in morning of days 1, 2 and 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The evening pain relief scale score</measure>
    <time_frame>measured in evening of days 1, 2 and 3</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">801</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Ketoprofen lysinate 12.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketoprofen lysinate 6.25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Matching placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KETOPROFEN(RP19583)</intervention_name>
    <description>Oral administration up to a maximum of 5 lozenges within a 24-hour period during 3 days</description>
    <arm_group_label>Ketoprofen lysinate 12.5 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KETOPROFEN(RP19583)</intervention_name>
    <description>Oral administration up to a maximum of 5 lozenges within a 24-hour period during 3 days</description>
    <arm_group_label>Ketoprofen lysinate 6.25 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral administration up to a maximum of 5 lozenges within a 24-hour period during 3 days</description>
    <arm_group_label>Matching placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Patients with a sore throat associated or not with an URTI &gt; or = 24 hours and &lt; or =&#xD;
             6 days' duration, in the absence of A.Streptococcus*,&#xD;
&#xD;
          -  Evidence of tonsillo-pharyngitis (TPA score &gt; or = 5) at inclusion,&#xD;
&#xD;
          -  With a score of throat soreness &gt; or = 6 (0-10 ordinal scale),&#xD;
&#xD;
          -  With a perception of swollen throat &gt; or = 60mm (VAS),&#xD;
&#xD;
          -  With a global throat pain intensity such as pain at swallowing&#xD;
&#xD;
          -  assessed by a VAS &gt; or = 60 mm.&#xD;
&#xD;
             *Specific exploration at Inclusion:&#xD;
&#xD;
          -  The Score of Mac Isaac will be performed by the investigator.&#xD;
&#xD;
          -  Presence of streptococcus will be assessed by a throat swab test Patients having a&#xD;
             positive swab test will not be included.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Patients having used any local medication containing a local oral anesthetic such as&#xD;
             lozenge, spray, mouth rinse or any topical throat treatment within 2 hours before&#xD;
             study entry&#xD;
&#xD;
          -  Patients with positive throat swab test for A.Streptococcus pharyngitis&#xD;
&#xD;
          -  Patients having used analgesics within 4 hours before study entry&#xD;
&#xD;
          -  Patients having used any long-acting or slow release analgesics within 12 hours before&#xD;
             study entry&#xD;
&#xD;
          -  Patients having used any anti inflammatory treatment 8-12 hours before study entry&#xD;
&#xD;
          -  Patients having used any anti histaminic 8-12 hours before study entry&#xD;
&#xD;
          -  Patients with pharyngeal paresthesia&#xD;
&#xD;
          -  Patients with pharyngeal mycosis&#xD;
&#xD;
          -  Patients with known history of ketoprofen, aspirin or other NSAID-induced bronchospasm&#xD;
&#xD;
          -  Hypersensitivity to ketoprofen or its excipients&#xD;
&#xD;
          -  Any disease that could compromise breathing such as bronchopneumonia or asthma&#xD;
&#xD;
          -  Evidence of mouth-breathing or uncomfortable coughing&#xD;
&#xD;
          -  Any chronic disease that requires a long period anti-inflammatory treatment&#xD;
&#xD;
          -  Any chronic disease that requires long term use of anticoagulants or use of&#xD;
             anticoagulants or anti-platelet agents one week before study entry,&#xD;
&#xD;
          -  Women known to be pregnant.&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilles Perdriset</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Col. Coyoacan</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Mexico</country>
    <country>Russian Federation</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2010</verification_date>
  <study_first_submitted>June 29, 2009</study_first_submitted>
  <study_first_submitted_qc>June 29, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2009</study_first_posted>
  <last_update_submitted>May 17, 2010</last_update_submitted>
  <last_update_submitted_qc>May 17, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 18, 2010</last_update_posted>
  <responsible_party>
    <name_title>Medical Affairs Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharyngitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketoprofen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

